Back to SGIOYView Full Landscape
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
10 competitors in Influenza
MRNAmRNA Flu vaccine
BNTXInfluenza and COVID-19 Combination A
Phase 3SNYA/H1N1 pandemic influenza vaccine (non- adjuvanted)
Phase 3NVSSurface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008
Phase 2BNTXInvestigational COVID-19 Vaccine
Phase 2Drug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA1/7/2021
Xofluza
Treatment of influenza Xofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above. Post exposure prophylaxis of influenza Xofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above. Xofluza should be used in accordance with official recommendations.
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts